ArticlePLoS pathogens2026
A feline coronavirus nucleocapsid protein disrupts ZC3HAV1-viral RNA association to counteract host RNA-level restriction.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronaviruses have evolved intricate mechanisms to evade host RNA surveillance systems and sustain efficient replication. The feline infectious peritonitis virus (FIPV), a highly lethal feline coronavirus that causes systemic vasculitis and fatal peritonitis, represents a major challenge in veterinary medicine and serves as a valuable model for studying conserved coronavirus-host interactions. Among coronavirus structural proteins, the nucleocapsid (N) protein not only packages the viral genome but also modulates host antiviral responses, yet its role in counteracting RNA restriction remains incompletely understood.
resultsUsing co-immunoprecipitation coupled with mass spectrometry screening, we identified the host RNA-binding antiviral factor ZC3HAV1 (also known as ZAP or PARP13) as a prominent N-associated host protein. ZC3HAV1 restricted FIPV replication by associating with viral RNA and reducing viral RNA accumulation and persistence. We show that the FIPV N protein associates with the RBD-containing region of ZC3HAV1 and that the ZC3HAV1-associated region of N contributes to efficient viral counter-restriction activity. Through coordinated protein-protein and protein-RNA interactions, FIPV N interferes with ZC3HAV1-viral RNA association, thereby supporting viral RNA accumulation and replication. Expression of FIPV N in a heterologous Japanese encephalitis virus system also alleviated ZC3HAV1-mediated RNA-level restriction, indicating that this antagonism activity is functionally transferable and not entirely dependent on FIPV-specific replication machinery. Despite the low CpG content of FIPV RNA, ZC3HAV1 efficiently associated with multiple viral transcripts, suggesting that ZC3HAV1-FIPV RNA recognition is not fully explained by overall CpG abundance and may also be influenced by subgenomic RNA context or structural features.
conclusionsThese findings reveal a previously unrecognized mechanism by which a highly pathogenic feline coronavirus circumvents host RNA restriction. By engaging the RBD-containing region of ZC3HAV1 and disrupting ZC3HAV1-viral RNA association, the FIPV N protein effectively attenuates ZC3HAV1-associated antiviral restriction and helps preserve viral RNA accumulation and persistence. This work expands the functional understanding of coronavirus N proteins beyond genome packaging and immune modulation, and provides new insight into FIPV-host interactions that may inform future studies of RNA-level counter-restriction mechanisms in other animal and human coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.